心脏手术中溶血与血红蛋白肾毒性的管理
本文综述体外循环(CPB)诱导的溶血在心脏手术后急性肾损伤(AKI)中的作用。CPB术后AKI发生于20%至30%的患者,游离血红蛋白通过氧化应激、一氧化氮耗竭和炎症导致肾损伤。针对游离血红蛋白的干预如结合珠蛋白、一氧化氮补充和抗氧化剂在现有临床数据中显示潜力,但需进一步研究验证。
要点
- CPB心脏手术后AKI发生率为20%至30%,溶血是重要机制。
- 游离血红蛋白通过氧化应激、一氧化氮耗竭和炎症引起肾损伤。
- 结合珠蛋白、一氧化氮和抗氧化剂等靶向治疗显示初步潜力。
核心结论
- CPB诱导的溶血与心脏手术后急性肾损伤相关。
- 靶向游离血红蛋白的治疗在现有临床数据中支持其潜在疗效,需进一步开发与验证。
研究设计与样本
- 综述,综合临床证据分析CPB诱导溶血在AKI中的作用及新兴干预措施。
主要发现
- CPB心脏手术后AKI影响20%至30%的患者。
- 游离血红蛋白触发氧化应激、耗竭一氧化氮并引发炎症,最终导致肾损伤。
临床怎么用
- 关注CPB术后溶血及游离血红蛋白毒性,作为AKI防治的潜在靶点。
- 结合珠蛋白、一氧化氮补充和抗氧化剂等干预措施在临床数据中显示潜力,可考虑进一步研究应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute kidney injury (AKI) affects 20% to 30% of patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). This review synthesizes clinical evidence indicating that CPB-induced hemolysis plays a pivotal role in the development of AKI. The pathogenesis involves cell-free hemoglobin, which triggers oxidative stress, depletes nitric oxide, and incites inflammation, culminating in renal damage. We highlight emerging interventions, including haptoglobin administration, nitric oxide supplementation, and antioxidants, which are promising in reducing the toxicity of cell-free hemoglobin and the incidence of AKI. Current clinical data support the potential efficacy of these treatments. Our analysis concludes that sufficient proof of concept exists to further develop and test these targeted therapies for preventing hemoglobin-induced AKI in patients undergoing CPB. Cardiopulmonary bypass-induced hemolysis is linked to acute kidney injury in cardiac surgery. Emerging therapies targeting cell-free hemoglobin, like haptoglobin, nitric oxide, and antioxidants, show promise in reducing kidney injury, highlighting the need for further research.
引用
- Schaer DJ, Schaer CA, Humar R, et al. Navigating Hemolysis and the Renal Implications of Hemoglobin Toxicity in Cardiac Surgery. Anesthesiology. 2024. PMID: 39159287. doi:10.1097/ALN.0000000000005109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。